Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PerioSept (3%) Adjunct to SRP in Periodontitis
NCT04093895Phase 2Completed
- Sponsor
- Geistlich Pharma AG
- Start
- Aug 2019
- Primary completion
- Jun 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of taurolidine in periodontitis, sponsored by Geistlich Pharma AG. Primary endpoint: Mean probing pocket depth reduction at 12 weeks. Started Aug 2019; status: completed.
02
Drugs
taurolidine
03
Conditions
periodontitis
Beyond the preview
Go deeper on NCT04093895.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04093895.